Your browser is no longer supported. Please, upgrade your browser.
Settings
NEO [NASD]
NeoGenomics, Inc.
Index- P/E- EPS (ttm)-0.03 Insider Own2.90% Shs Outstand110.46M Perf Week4.77%
Market Cap6.57B Forward P/E188.65 EPS next Y0.30 Insider Trans-29.46% Shs Float110.38M Perf Month3.66%
Income-4.90M PEG- EPS next Q0.06 Inst Own89.70% Short Float4.42% Perf Quarter32.99%
Sales425.30M P/S15.45 EPS this Y16.20% Inst Trans0.08% Short Ratio5.89 Perf Half Y52.59%
Book/sh6.03 P/B9.29 EPS next Y318.31% ROA-0.60% Target Price52.50 Perf Year69.84%
Cash/sh2.42 P/C23.16 EPS next 5Y20.00% ROE-0.80% 52W Range20.47 - 57.07 Perf YTD4.07%
Dividend- P/FCF- EPS past 5Y30.80% ROI2.70% 52W High-1.82% Beta0.72
Dividend %- Quick Ratio6.20 Sales past 5Y36.20% Gross Margin41.90% 52W Low173.72% ATR2.23
Employees1700 Current Ratio6.50 Sales Q/Q19.80% Oper. Margin-4.40% RSI (14)61.55 Volatility3.89% 4.02%
OptionableYes Debt/Eq0.26 EPS Q/Q91.40% Profit Margin-1.20% Rel Volume0.87 Prev Close55.29
ShortableYes LT Debt/Eq0.25 EarningsOct 27 BMO Payout- Avg Volume827.09K Price56.03
Recom1.50 SMA203.66% SMA5012.24% SMA20047.23% Volume716,682 Change1.34%
Dec-11-20Resumed BTIG Research Buy $60
Oct-28-20Reiterated Needham Buy $39 → $46
Sep-09-20Initiated Morgan Stanley Overweight $46
Aug-28-20Initiated Guggenheim Buy $46
Jul-29-20Reiterated Needham Buy $33 → $39
Jun-25-20Initiated BofA/Merrill Buy $34
Apr-21-20Resumed Stephens Overweight $33
Mar-02-20Resumed Craig Hallum Buy $38
Feb-28-20Upgrade First Analysis Sec Outperform → Strong Buy
Jan-23-20Downgrade First Analysis Sec Strong Buy → Outperform $29 → $35
Oct-30-19Reiterated Needham Buy $27 → $29
May-01-19Reiterated Needham Buy $22 → $24
Mar-29-19Reiterated Needham Buy $19 → $22
Jan-03-19Initiated Needham Buy $14
Oct-24-18Upgrade First Analysis Sec Outperform → Strong Buy $18
Aug-21-18Initiated Leerink Partners Outperform $18
May-02-18Downgrade First Analysis Sec Overweight → Equal-Weight $11
Sep-11-17Downgrade BTIG Research Buy → Neutral
Aug-24-17Initiated Gabelli & Co Buy $9
Dec-15-16Initiated Cantor Fitzgerald Overweight $11
Jan-10-21 11:00AM  
Jan-06-21 11:00PM  
Jan-05-21 04:05PM  
Jan-04-21 07:30AM  
Dec-16-20 05:33PM  
Nov-29-20 06:44AM  
Nov-16-20 08:00AM  
Nov-13-20 04:05PM  
Nov-09-20 07:00AM  
Oct-29-20 09:34AM  
Oct-28-20 10:58AM  
Oct-27-20 02:00PM  
10:45AM  
07:38AM  
07:00AM  
Oct-20-20 12:31PM  
Oct-15-20 09:00AM  
Oct-13-20 01:31PM  
09:00AM  
Oct-01-20 07:00AM  
Sep-10-20 04:05PM  
Sep-07-20 11:40AM  
Aug-31-20 05:00PM  
Aug-28-20 10:16AM  
Aug-06-20 01:43PM  
Aug-05-20 11:11AM  
Jul-30-20 10:52AM  
Jul-28-20 01:30PM  
10:34AM  
09:55AM  
08:59AM  
07:00AM  
Jul-21-20 12:31PM  
Jul-20-20 07:00AM  
Jul-12-20 06:12AM  
Jul-04-20 08:18PM  
Jul-01-20 07:00AM  
Jun-29-20 07:00AM  
Jun-25-20 10:10AM  
Jun-18-20 12:27PM  
Jun-12-20 01:50AM  
Jun-10-20 06:44PM  
Jun-02-20 04:05PM  
Jun-01-20 04:05PM  
May-26-20 07:20AM  
05:00AM  
May-19-20 12:00AM  
May-11-20 04:05PM  
May-09-20 11:47AM  
May-05-20 08:00AM  
Apr-30-20 12:07PM  
06:00AM  
Apr-29-20 05:20PM  
06:33AM  
Apr-28-20 04:00PM  
09:35AM  
07:00AM  
Apr-27-20 04:00PM  
Apr-09-20 07:00AM  
Apr-03-20 07:00AM  
Apr-01-20 07:00AM  
Mar-29-20 12:12PM  
Mar-27-20 07:58AM  
Mar-02-20 07:00AM  
Mar-01-20 09:10AM  
Feb-28-20 07:00AM  
Feb-27-20 09:55AM  
07:08AM  
06:30AM  
Feb-20-20 12:31PM  
Feb-06-20 07:00AM  
Feb-05-20 07:00AM  
Jan-30-20 11:30AM  
Jan-17-20 10:45AM  
Jan-14-20 07:55AM  
Jan-10-20 08:40AM  
Dec-12-19 07:10PM  
Nov-06-19 04:05PM  
07:00AM  
Nov-05-19 06:01PM  
Nov-01-19 11:34AM  
Oct-29-19 08:55AM  
07:00AM  
Oct-24-19 02:07PM  
Oct-23-19 11:06AM  
Oct-01-19 04:05PM  
Sep-25-19 04:05PM  
Sep-17-19 07:49AM  
Sep-09-19 07:12AM  
Sep-03-19 04:15PM  
Aug-12-19 08:38AM  
08:00AM  
Aug-08-19 08:45AM  
Aug-05-19 04:20PM  
Aug-02-19 06:41AM  
Aug-01-19 05:34PM  
11:01AM  
Jul-31-19 07:00AM  
Jul-30-19 06:23PM  
09:35AM  
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides morphologic analysis which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. has a strategic collaboration with Inivata Limited for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JONES STEVEN CDirectorJan 07Option Exercise7.15100,000715,0001,100,000Jan 11 05:24 PM
JONES STEVEN CDirectorJan 07Option Exercise11.7917,286203,83590,218Jan 11 05:24 PM
Weiss Lawrence MartinChief Medical OfficerDec 14Option Exercise9.40109,0041,024,986120,721Dec 15 08:51 PM
JONES STEVEN CDirectorDec 14Sale51.6725,0001,291,7501,000,000Dec 14 05:49 PM
Weiss Lawrence MartinChief Medical OfficerDec 14Sale51.0620,2001,031,412100,521Dec 15 08:51 PM
BALLIET JENNIFERVP and Chief Culture OfficerDec 11Option Exercise8.0315,000120,45039,980Dec 11 05:57 PM
BALLIET JENNIFERVP and Chief Culture OfficerDec 11Sale49.9915,000749,85024,980Dec 11 05:57 PM
JONES STEVEN CDirectorDec 11Sale50.5225,0001,263,0001,025,000Dec 14 05:49 PM
JONES STEVEN CDirectorDec 10Sale50.3020,0001,006,0001,050,000Dec 14 05:49 PM
JONES STEVEN CDirectorDec 07Sale49.4545,6582,257,7881,070,000Dec 07 06:23 PM
JONES STEVEN CDirectorDec 04Sale48.0764,3943,095,4201,115,658Dec 07 06:23 PM
Johnson Kevin CDirectorDec 04Sale47.8824,6831,181,82230,983Dec 07 06:19 PM
JONES STEVEN CDirectorDec 03Sale48.0319,948958,1021,180,052Dec 07 06:23 PM
Bonello WilliamPresident, InformaticsDec 02Option Exercise8.038,00064,24020,060Dec 04 06:03 PM
Bonello WilliamPresident, InformaticsDec 02Sale46.808,000374,40012,060Dec 04 06:03 PM
CARDOZA GEORGEPresident, Pharma ServicesNov 25Option Exercise7.5277,074579,596447,976Nov 25 06:04 PM
CARDOZA GEORGEPresident, Pharma ServicesNov 25Sale45.4877,0743,505,326370,902Nov 25 06:04 PM
CARDOZA GEORGEPresident, Pharma ServicesNov 24Option Exercise7.5272,926548,404423,828Nov 25 06:04 PM
CARDOZA GEORGEPresident, Pharma ServicesNov 24Sale45.1952,9262,391,726370,902Nov 25 06:04 PM
VAN OORT DOUGLAS MChairman and CEONov 16Option Exercise7.5220,000150,4002,522,790Nov 16 08:30 PM
VAN OORT DOUGLAS MChairman and CEONov 16Sale42.34100,0004,234,0002,422,790Nov 16 08:30 PM
HIPP RAYMOND RDirectorNov 16Sale42.2870,0002,959,60066,800Nov 18 06:53 PM
VAN OORT DOUGLAS MChairman and CEONov 13Option Exercise7.52358,7522,697,8152,621,542Nov 16 08:30 PM
VAN OORT DOUGLAS MChairman and CEONov 13Sale41.56118,7524,935,3332,502,790Nov 16 08:30 PM
VAN OORT DOUGLAS MChairman and CEONov 12Option Exercise7.52121,248911,7852,384,038Nov 16 08:30 PM
VAN OORT DOUGLAS MChairman and CEONov 12Sale42.18121,2485,114,2412,262,790Nov 16 08:30 PM
Pedulla Denise EGeneral CounselNov 10Option Exercise7.8515,000117,75058,988Nov 12 06:00 PM
Pedulla Denise EGeneral CounselNov 10Sale42.002,26295,00456,726Nov 12 06:00 PM
JONES STEVEN CDirectorSep 29Sale36.95141,0495,211,7611,200,000Sep 30 06:25 PM
JONES STEVEN CDirectorSep 29Sale36.5581,0002,960,55097,932Sep 30 06:25 PM
JONES STEVEN CDirectorSep 28Sale36.3438,9511,415,4791,341,049Sep 30 06:25 PM
JONES STEVEN CDirectorSep 28Sale36.5619,000694,640178,932Sep 30 06:25 PM
CROWTHER BRUCE KDirectorSep 24Option Exercise9.118,33375,91454,816Sep 24 09:02 PM
CROWTHER BRUCE KDirectorSep 24Sale35.018,333291,73846,483Sep 24 09:02 PM
CROWTHER BRUCE KDirectorSep 22Sale35.682,40085,63246,483Sep 24 09:02 PM
JONES STEVEN CDirectorSep 10Sale37.1337,9911,410,6061,380,000Sep 10 06:16 PM
JONES STEVEN CDirectorSep 09Sale36.9871,5832,647,1391,417,991Sep 10 06:16 PM
JONES STEVEN CDirectorSep 08Sale36.1310,426376,6911,489,574Sep 10 06:16 PM
CARDOZA GEORGEPresident, Pharma ServicesAug 06Option Exercise7.15100,000715,000433,402Aug 10 06:19 PM
HANNAH ALISON L.DirectorAug 06Option Exercise7.2710,00072,70088,796Aug 10 06:22 PM
CARDOZA GEORGEPresident, Pharma ServicesAug 06Sale39.3582,5003,246,375350,902Aug 10 06:19 PM
BALLIET JENNIFERVP and Chief Culture OfficerAug 03Option Exercise7.5213,00097,76037,980Aug 04 06:01 PM
Bonello WilliamPresident, InformaticsAug 03Option Exercise7.5722,000166,44234,060Aug 04 06:33 PM
Bonello WilliamPresident, InformaticsAug 03Sale38.6122,000849,42012,060Aug 04 06:33 PM
BALLIET JENNIFERVP and Chief Culture OfficerAug 03Sale39.2513,000510,25024,980Aug 04 06:01 PM
SHOVLIN ROBERT J.President, Clinical ServicesJul 30Option Exercise9.9483,391829,126229,626Aug 03 07:26 PM
SHOVLIN ROBERT J.President, Clinical ServicesJul 30Sale38.1781,3563,105,359148,270Aug 03 07:26 PM
CROWTHER BRUCE KDirectorMay 01Option Exercise4.7810,00047,80046,185May 04 05:34 PM
JONES STEVEN CDirectorMar 13Option Exercise4.78125,000597,5001,500,000Mar 16 06:45 PM
SHOVLIN ROBERT J.President, Clinical ServicesMar 04Option Exercise8.0396,167772,221249,733Mar 05 08:14 PM
SHOVLIN ROBERT J.President, Clinical ServicesMar 04Sale30.8698,0933,027,150151,640Mar 05 08:14 PM
JONES STEVEN CDirectorMar 02Sale28.77297,3008,554,25230,476Mar 04 07:17 PM